On April 7th the Wageningen Centre for Systems Biology (WCSB) will organise a seminar on systems biology. The seminar is free, will take an hour and will be followed by drinks. No registration is necessary, so feel free to come by!
Prof. Dr. Timothy R.D.J. Radstake, MD, Ph.D, Director Utrecht Infection and Immunity FOCIS center of excellence and Department of Rheumatology & Clinical Immunology, Laboratory of Translational Immunology, University Medical Center Utrecht
"A systems Medicine approach to move towards true personalised medicine for inflammatory conditions"
Professor Radstake MD, Ph.D. attended medical school at the Radboud University in Nijmegen the Netherlands where he graduated in 2000. He next performed his PhD on the genetic factors that determine the susceptibility to Rheumatoid arthritis and the role of dendritic cells in this conditions that he finished in 2003 under the supervision of Professors van Riel and van den Berg.
Soon after that he started his own research line on translational rheumatology with the ultimate aim to translate clinical problems to novel therapeutic targets. Although starting his research in rheumatoid arthritis, over the years his group investigated a broader spectrum of rheumatic conditions including psoriatic arthritis and systemic sclerosis. From 2007 – 2008 prof. Radstake did a post-doctoral fellowship on the department of rheumatology at the Boston University School of Medicine (prof. R. Lafyatis) where he held a chair until 2014.
From March 2012 he holds the chair on translational immunology at the university medical Center Utrecht were his research team, comprising roughly 40 fte, focuses on a systems medicine approach with the ultimate goal to achieve personalized health care on the basis of molecular taxonomy rather that clinical diagnosis. A side to his clinical work and role as director of the Utrecht Infection & Immunity FOCIS center of excellence, he is current involved as a entrepreneur in multiple projects to bring potential therapeutic targets to the market, anti-CXCL4 as a novel therapeutic entry-point for scleroderma being the most progressed.
Audia S, et al. & Radstake TRDJ. Splenic TFH expansion participates in B cell differentiation and antiplatelet antibody production via CD40L and IL-21 during adult immune thrombocytopenia. Blood 2014.
L. van Bon, et al & Radstake TRDJ. Proteome-wide analysis identifies the chemokine CXCL4 as a clinical marker that drives critical pathological events in systemic sclerosis. New England Journal of Medicine 2014 Jan 30;370(5):433-43.
Radstake TRDJ et al. Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nature Genetics 2010; May;42(5):426-9.
More information about WCSB and the 14 different projects can be found on the website www.wur.nl/systemsbiology.